









Markets
/
Stocks
/
nasdaq-bcda
/

BioCardia Inc

BCDA

View Detailed Chart

2.130USD

-0.040-1.87%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

9.97MMarket Cap

LossP/E TTM



BioCardia Inc

2.130

-0.040-1.87%

Overview Company Financials

Financials

Intraday

30m

Today

-1.87%

5 Days

-9.36%

1 Month

+0.47%

6 Months

-11.62%

Year to Date

-2.29%

1 Year

-29.00%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

BUY

Current Rating

15.500

Target Price

627.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

BioCardia Inc

BCDA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(9)

Neutral(3)

Buy(0)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.045

Neutral

RSI(14)

43.026

Neutral

STOCH(KDJ)(9,3,3)

19.008

Neutral

ATR(14)

0.118

Low Volatility

CCI(14)

-189.356

Sell

Williams %R

79.474

Sell

TRIX(12,20)

0.122

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.194

Sell

MA10

2.266

Sell

MA20

2.280

Sell

MA50

2.190

Sell

MA100

2.287

Sell

MA200

2.300

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

Ticker SymbolBCDA

CompanyBioCardia Inc

CEODr. Peter Altman, Ph.D.

Websitehttps://www.biocardia.com/